FDA, Mounjaro

FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
Zepbound, Mounjaro shortages are resolved, FDA confirms
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List
The FDA removed Eli Lilly’s LLY tirzepatide injection products from the drug shortage list after determining that Lilly’s supply is currently meeting or exceeding demand and will continue to do so in the future.
FDA: No more need for compounded versions of Mounjaro, Zepbound
The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the production of compounded versions of the drugs, Bloomberg reported Dec. 19.
FDA keeps Mounjaro off shortage list after reevaluation
The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a reevaluation of its decision to remove it from federal drug shortage list amid intense pushback from compounded drug manufacturers.
Shortage of popular weight loss drug is over -- is that good news for all patients?
Dr. Todd Ellerin, vice chair of medicine at South Shore Health, shares the latest from the FDA about the availability of these popular drugs.
FDA reaffirms end of Mounjaro shortage
FDA resolves two-year shortage of Mounjaro and Zepbound after pushback from compounding pharmacies. Lawsuit filed, but agency reaffirms decision.
PharmiWeb3d
Best Mounjaro Alternative Over the Counter: Cheaper, Safer Alternatives to Tirzepatide OTC
If you are considering a natural over the counter Mounjaro alternative for 2025 - we have the top 3 options for you. SAN ...
Lilly's Mounjaro more popular than Wegovy in UK's private obesity drug market
Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...
Eli Lilly’s Mounjaro Won’t Have Separate Sleep Apnea Label in EU
Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...
Medical News Today5d
How to Get Mounjaro: What to Know About a Mounjaro Prescription Online, According to Our Experts
Mounjaro is a prescription glucagon-like peptide-1 (GLP-1) drug with the active ingredient tirzepatide. Doctors prescribe it for the treatment of type 2 diabetes, but they may also prescribe it ...
The Daily Telegraph11d
What is Mounjaro? The Ozempic-style weight-loss drug being rolled out on the NHS
But Ozempic and Wegovy – and their newer cousin, Mounjaro – are expensive, and mostly only available on private prescription. For the past year, overweight Britons have been waiting for these ...
Monthly Prescribing Reference1d
FDA Says Shortage of GLP-1 Tirzepatide Is Over
Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss).
Moneyweb1d
ASPEN PHARMACARE HOLDINGS LIMITED – Aspen | Lilly agreement: Aspen announces local availability of Lilly’s Mounjaro
Aspen Holdings (‘Aspen’) announced that it had entered into a distribution and promotion agreement with Eli Lilly Export S ...
Business Wire2d
Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement
EDO, the TV outcomes company, has released its Q3 2024 Diabetes Convergent TV Outcomes Report, providing critical insights into the diabetes category ...